Sartorius Honored as Overall Best Bioprocessing Supplier Award Winner at Europe Bioprocessing Excellence Awards 2021

Sartorius, a leading international partner of life science research and the biopharmaceutical industry, was named the award winner for “Overall Best Bioprocessing Supplier” at the Europe Bioprocessing Excellence Awards 2021. According to award organizer IMAPAC, the awards seek to recognize exceptional bioprocessing experts, organizations, and technologies that facilitate biomanufacturing excellence at enhanced speed, reduced cost, and superior quality across Europe and the rest of the world.

“Sartorius is proud of its leadership and innovations in bioprocessing and values the strong relationships we have built with partners and customers throughout the industry,” said Christopher Mach, Head of Key Account Management at Sartorius. “We remain committed to helping our customers create better patient outcomes through the development of new and improved therapies. We’re honored to be named ‘Overall Best Bioprocessing Supplier’ at this year’s Bioprocessing Excellence Awards.”

The award ceremony was held in conjunction with Biologics Contract Manufacturing Europe 2021 and 4th Biologics World Nordic 2021 conference events, and René Fáber, Head of BPS Division, Sartorius, accepted the award virtually on behalf of Sartorius. Winners were determined by a panel of four external judges who are industry professionals, community experts, regional representatives, and past winners.

A profile of Sartorius

The Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions complementary technologies. In fiscal 2020, the company earned sales revenue of some 2.34 billion euros. At the end of 2020, nearly 11,000 people were employed at the Group’s approximately 60 manufacturing and sales sites, serving customers around the globe.